Key result
Expression of the coxsackievirus and adenovirus receptor (CAR) and its D2 deletion mutant inhibited the tumorigenicity of U- glioma cells both in vitro and in vivo.
The coxsackievirus and adenovirus receptor (CAR) acts as a tumor suppressor in glioma cells, and its extracellular D2 domain is not required for this inhibitory effect.
Answers are grounded in this paper and cite their sources.
Supports CAR as tumor suppressor in glioma models; leaves open human translation.
The coxsackievirus and adenovirus receptor (CAR) is a membrane glycoprotein with a cytoplasmic domain, a transmembrane domain and an extracellular region consisting of two immunoglobulin-like domains, an amino-terminal immunoglobulin variable (IgV)-related domain (D1), which is distal to the cell surface, and a proximal IgC2 domain (D2). The coxsackievirus and adenovirus receptor has been shown to exhibit tumour suppression activity in human bladder and prostate cancer cells. In the current paper, we demonstrate that CAR is a tumour suppressor in glioma cells and that the extracellular D2 domain is not required for this inhibitory effect. This finding provides a biological basis for the observation that expression of CAR is downregulated in malignant glioma cells. This suggests that strategies to redirect adenoviruses to achieve CAR-independent infection will be necessary to realise the full potential of adenoviral vectors for cancer gene therapy.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2003) studied Malignant glioma. Expression of coxsackievirus and adenovirus receptor (CAR) and its mutants vs. Parental U-118 MG cells or empty vector was evaluated on Tumor volume (in vivo) and colony formation (in vitro) (p=<0.05). Expression of the coxsackievirus and adenovirus receptor (CAR) and its D2 deletion mutant inhibited the tumorigenicity of U- glioma cells both in vitro and in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: